New clinical data suggests that Novera Retatrutide, a dual-action medication from Novo Nordisk, could offer a substantial breakthrough in body control. Beyond many existing drugs, Retatrutide impacts both GLP-1 and GIP, potentially resulting to greater reductions in body and more favorable outcom